SlideShare a Scribd company logo
1 of 28
Download to read offline
RECALL
PROCEDURE
S
07/15/13 1
TABLE OF CONTENTS:
I. Recall Page # 3
II. FDA responsibilities Page # 4
i. Responsibilities of OE/DCMO Page # 5
ii. Responsibilities & procedures - OE/DCP Page # 6
iii. Responsibilities & procedures – OE/DCIQA Page #6
III. Recall Enterprise System (RES) Page # 7
IV. Center Recall Unit (CRU) Page # 8
V. Health Hazard Evaluation (HHE) Page # 9
VI. Recall Initiation Page # 10
VII. Recall Classification Page # 11
i. Class I Recall Page # 12
ii. Class II Recall Page # 13
iii. Class III Recall Page # 14
VIII. Alerting the public Page # 15
IX. Monitoring Recall Effectiveness Page # 16
X. Termination of Recall Page # 17-18
XI. Responsibilities of Recalling Firm Page # 19
i. Preparing of the Recall Page # 20
ii. Determining the Scope of the Recall Page # 21
iii. Determining the Depth of the Recall Page # 22
iv. Communicating with FDA Page # 23
v. Communicating with Consignees Page # 25
vi. Press release Page # 25
XII. Drug Recalls in 2013. Page # 26-28
07/15/13
2
RECALL
• Recall means a firm’s removal or correction of a
marketed product(s) that the Food and Drug
Administration considers to be in violation of the
laws it administers and against which the agency
would initiate legal action, e.g., seizure.
OR
• Recalls are an alternative appropriate method of
removing or correcting marketed consumer products,
their labeling, and/or promotional literature that
violates the laws administered by FDA.
07/15/13 3
FDA RESPONSIBILITIES
• FDA is involved in recall procedures.
• Monitor the recall by reviewing firm’s status reports and conducting audit checks
(District)
• Discuss and approve recall strategy –including press releases (District/Center
-Office of Public Affairs for press)
• Classify the recall (Center)
• Terminate the recall (District Class II and III; Center approval for class I)
• FDA will take appropriate regulatory action or other measures when the firm fails
to recall violative product or when a recall action fails.
• These actions will be taken in consultation and coordination with the district
compliance branch, the appropriate center recall and compliance staffs, OE/DCMO
and when indicated, the officer of Chief Counsel, when:
– A firm refuses to recall or sub-recall after being requested to do so by FDA;
– A firm fails to complete recall in a timely fashion;
– The agency has reason to believe that a recall strategy is not effective.
07/15/13 4
• Responsibility of Office of Enforcement / Division of
Compliance Management and Operations
–OE/ DCMO is the agency’s headquarters contact and focal point
for information, advice, and direction for field recall operations and
remains involve with each recall throughout its process.
–If required, it may direct appropriate follow up actions by the
field.
–It periodically reviews all agency recall activities to ensure that
current policy & procedures are being applied to recalls and
recommends changes are appropriate.
–It informs OE/DCIQA of recalls that may affect govt. agencies.
–It evaluates the overall effectiveness of recall activities.
–It communicates trends, common cause of recalls, control
weakness, etc., having the needs for this information.
07/15/13 5
• Responsibilities & Procedures - Office of Enforcement/
Division of Compliance Policy
–OE/DCP reviews and resolves compliance policy issues related to
recalls.
–The division reviews recall action memorandums when requested
by OE/DCMO.
–OE/DCP provides written response to OE/DCMO.
• Responsibilities & Procedures - Office of
Enforcement/Division of Compliance information &
Quality Assurance
–OE/DCIQA receives recall information from OE/DCMO when the
identified consignees include government agencies.
–It forwards the information, as appropriate, to the applicable
government agencies.
07/15/13 6
RECALL ENTERPRISE SYSTEM
• The Recall Enterprise System (RES)is an electronic data system used by FDA
recall personnel to submit, update, classify, & terminate recalls.
• The RES increases efficiency in processing recall information by:
– Allowing field coordinators to input recall information via on-line, internet
system;
– Allowing users to build a record of the entire recall by entering information as
it becomes available thus reducing preparation time and providing consistency
throughout the agency;
– Reducing duplication of efforts between the Field officer, OE, the centers, and
Office of public affairs;
– Increasing communication of recall information between field, headquarters
and the appropriate center(s) office;
– Using a uniform Health Hazard Evaluation (HHE) form or a form equivalent to
HHE form to promote consistency in evaluating potential health hazards;
– Providing the public with “real-time” information about the FDA recall
process.
07/15/13 7
CENTER RECALL UNIT(CRU)
• The Center recall unit:
1. Initiates a health hazard evaluation (HHE)
2. Finalizes a recall strategy
3. Classifies the recall and, for Class I recalls,
prepares an Action memorandum for Center
Director or his/her designee concurrence before
forwarding it to OE/DCMO and the ACRA; and,
4. Updates RES with classification, audit strategy,
and any recommendations, and posts the
information to the internet.
07/15/13 8
HEALTH HAZARD
EVALUATION
•Diseases or injuries which have already occurred
•Existing conditions that can contribute to a clinical
condition
•Population
•Seriousness of hazard
•Likelihood of occurrence of hazard
•Immediate and long term consequences
07/15/13 9
RECALL INITIATION
• Recall may initiated in three ways:
1. Firm initiated Recalls: A manufacturer or distributor may
voluntarily initiate a recall at any time.
2. FDA requested Recalls: Under certain urgent situations,
FDA may request that a manufacturer or distributor recall
a product.
3. FDA Ordered Recalls: Under certain authorities, FDA
may mandate a recall. It includes:
– Mandatory Device recalls
– Mandatory of biological products
– Mandatory recall of human tissue intended for transplantation
– Infant formula
– Interstate milk shipments
– Tobacco products
07/15/13 10
RECALL CLASSIFICATION
• Numerical designation (i.e., I, II, or III) is assigned by
FDA to a particular product recall to indicate the
relative degree of health hazard presented by the
product being recalled.
07/15/13 11
• CLASS I RECALLS
Class I is a situation in which there is a reasonable probability that
the use of, or exposure to, a violative product will cause serious
adverse health consequences or death.
Examples of Class I Recalls
•Pathogens in ready-to-eat food: Salmonella, Listeria
monocytogenes, E. coli, Clostridium
•High levels of sulfites
•High levels of heavy metals
•Choking hazards for susceptible populations
07/15/13 12
• CLASS II RECALLS
Class II is a situation in which use of, or exposure to, a violative
product may cause temporary or medically reversible adverse
health consequences or where the probability of serious adverse
health consequences is remote.
Examples of Class II Recalls
•Foreign objects that pose a physical hazard
•Pathogens: Shigella, hepatitis A, Cyclospora, Cryptosporidium
07/15/13 13
• CLASS III RECALLS
Class III is a situation in which use of, or exposure to, a violative
product is not likely to cause adverse health consequences.
• Example of Class III Recalls
An example might be bottles of aspirin that contains 90 tablets
instead of the 100 stated on the label.
07/15/13 14
ALERTING THE PUBLIC
• FDA seeks publicity about a recall only when it believes the public needs
to be alerted to a serious hazard.
• When a recalled product has been widely distributed, the news media is a
very effective way to reach large numbers of people.
• FDA can hold press conferences, issue press releases, and post updates to
its Web site regularly, to alert people.
• Not all recalls are announced in the media. But all recalls go into FDA's
weekly Enforcement Report. This document lists each recall according to
classification, with the specific action taken by the recalling firm.
• "It's about being as transparent as possible," says Catherine McDermott,
public affairs manager in the Division of Federal-State Relations in FDA's
Office of Regulatory Affairs. "If we feel there is that much of a health risk,
we will offer media updates every day to give new information, and all that
we know gets posted to FDA's Web site."
07/15/13 15
MONITORING RECALL
EFFECTIVENESS
• FDA evaluates whether all reasonable efforts have been made to remove or
correct a product.
• A recall is considered complete after all of the company's corrective
actions are reviewed by FDA and deemed appropriate.
• After a recall is completed, FDA makes sure that the product is destroyed
or suitably reconditioned, and investigates why the product was defective
in the first place
• A recalling firm may be unable to check the effectiveness of its recall when
a recall extends to the consumer-user level, the confidential business
record of a firm’s customers are not accessible, wholesalers, distributors or
retailors do not cooperate, or because an urgency of the situation requires
an all-out effort.
• In such cases, when a recalling firm unable to check its effectiveness, FDA
will directly assist in this activity and, where necessary, seek assistance
from cooperating state and local agencies.
07/15/13 16
TERMINATION OF RECALL
• FDA will terminate a recall when the monitoring district office
determines that the recalling firm has completed all recall
activity, including monitoring and final product disposition.
• The district will notify the recalling firm by a letter that FDA
considers the recall terminated.
• Termination of Class I recall and a Safety Alert requires center
concurrence. When the monitoring district concludes that such
a recall and a Safety Alert has been completed, the district
recall coordinator will enter the information required for
termination in RES on the “Summary & Termination “ page
then verify the information then send an email to the CRU
recommending termination.
07/15/13 17
• Upon receipt of the termination recommendation email, the
CRU will access RES, review the termination information and
change the “recall status” field to “terminated” and generates
an email to the district and OE/DCMO advising that the recall
is terminated
• Center approval is not required for Class II and III recall
terminations.
• As a rule FDA should terminate the recall within three months
after the firm completes the recall.
07/15/13 18
RESPONSIBILTIESOF
RECALLING FIRM
07/15/13 19
Preparing for a recall
• Review available recall guidance
• Develop a recall plan
• Maintain manufacturing and distribution records in a
manner to facilitate a timely and effective recall
• Identify finished products with a lot number/code
07/15/13 20
Determining the scope of the
recall.
•When did the problem start/end?
•Can additional lots/products be affected other than the
lot/product analyzed and found adulterated?
•How many sizes/labels for the product?
•Is the product coded with a lot number?
•Shelf life of product
07/15/13 21
Determining the depth of the
recall
•Class I recalls generally to consumer/user depth via
press release
•Class II generally to retail depth; some to
consumer/user via press release
•Class III generally to retail depth when problem when
problem obvious to consumer
07/15/13 22
Communicating with the FDA
• Notify FDA District Recall Coordinator and provide information in a
timely manner
• Info needed by FDA includes:
– Product (identity, size and type of containers, brand names, lot numbers, whether
refrigerated/frozen/shelf stable)
– Codes
– Amount manufactured and amount distributed
– Number of and types of consignees
– Area of distribution
– Reason for recall
• Discuss recall strategy with FDA (including disposition of recalled
product)
• Let FDA review text of phone notifications, written recall notifications,
press releases (follow models provided in FDA guidance)
• Provide FDA with consignee list
• Provide actual labels or clear photos of labels07/15/13 23
Communicating with Consignees
•Be brief and to the point
•Identify clearly the product, size, lot number(s), code(s) or serial
number(s) and any other pertinent descriptive information to
enable accurate and immediate identification of the product
•Explain concisely the reason for the recall and the hazard
involved, if any
•Provide specific instructions on what should be done with
respect to the recalled products
•Provide a ready means for the recipient of the communication to
report to the recalling firm whether it has any of the product
•Provide sub-recall instructions (if necessary)
•Re-contact non-responders and conduct effectiveness checks
07/15/13 24
Press release
•Follow FDA models as closely as possible –“fill in the
blanks”
•Do not change hazard statement –don’t take out “life
threatening”
•Issue press release to Associated Press
•Provide FDA with confirmation that press release was
sent to AP
•FDA will issue if firm will not or if firm’s is
inadequate
07/15/13 25
DRUG RECALLS in 2013
07/15/13 26
drugsrecall in 2013
Date Brand Name Product Description Reason/ Problem Company
07/03/2013 Estarylla
Estarylla
(norgestimate and
ethinyl estradiol)
tablets
Report of a
placebo tablet
present in a row
of active tablets
Sandoz
06/30/2013 Nexus, APP
Benztropine
Mesylate Injection
Glass particles Fresenius Kabi USA
06/19/2013 Rugby
Enteric Coated
Aspirin Tablets,81
mg
May Contain
Acetaminophen
500 mg tablets
Advance
Pharmaceutical Inc.
06/13/2013
Sagent Pharmaceuticals, Inc.
Vecuronium
Bromide for
Injection
Due to elevated
impurity levels
Sagent
Pharmaceuticals, Inc.
06/11/2013 Bethel Weight Loss Pills
Contains
Undeclared Drug
Ingredient
Bethel Nutritional
Consulting, Inc.
06/10/2013 ZyGenerics
Warfarin 2 mg
Tablets
Oversized tablet
Zydus
Pharmaceuticals
USA Inc.
06/07/2013
Sagent Pharmaceuticals,
Inc.
Vecuronium
Bromide for
Injection
Due to elevated
impurity levels
Sagent
Pharmaceuticals, Inc.
07/15/13 27http://www.fda.gov/Safety/Recalls/default.htmhttp://www.fda.gov/Safety/Recalls/default.htm
07/15/13 28
Date Brand name Product
Description
Problem/Reason Company
05/29/2013
Lowlite, Olympia
Pharmacy
All Sterile Products
Potential for non-
sterility
Lowlite Investments,
Olympia Pharmacy
05/28/2013
Main Street Family
Pharmacy
All Sterile Products
Potential for non-
sterility
Main Street Family
Pharmacy, LLC
05/25/2013 Fresenius Kabi USA
Magnesium Sulfate
Injection USP
Glass Particles Fresenius Kabi USA
05/21/2013
JaDera, Xiyouji
Qingzhi
Weight loss
supplement
Unapproved New
Drug
Dolphin Intertrade
Corp
05/20/2013 Sandoz
Methotrexate
Sodium, USP, 25
mg/mL, 40 mL vial
injectable vials
Particulate
material in vials
Sandoz US
05/15/2013 Pentec Health
In-date nutritional
prescriptions for
renal patients
Lack of sterility
assurance
Pentec Health
05/10/2013 Hospira
Piperacillin and
Tazobactam for
Injection
Precipitation/Cryst
allization in IV
bag
Apotex Corp.
http://www.fda.gov/Safety/Recalls/default.htm

More Related Content

What's hot

Pharmaceutical Complaints
Pharmaceutical ComplaintsPharmaceutical Complaints
Pharmaceutical ComplaintsTeny Thomas
 
Pharmaceutical documentation
Pharmaceutical documentationPharmaceutical documentation
Pharmaceutical documentationK V NANDA KUMAR
 
Complaints and recall handling
Complaints and recall handlingComplaints and recall handling
Complaints and recall handlinghusna05
 
BMR (Batch Manufacturing Record)
BMR (Batch Manufacturing Record)BMR (Batch Manufacturing Record)
BMR (Batch Manufacturing Record)Ram Mohan S R
 
Market complaints & product recall
Market complaints & product recallMarket complaints & product recall
Market complaints & product recallkirankumarsolanki3
 
Vendor qualification
Vendor qualificationVendor qualification
Vendor qualificationShihabPatel
 
BATCH MANUFACTURING RECORD
BATCH MANUFACTURING RECORDBATCH MANUFACTURING RECORD
BATCH MANUFACTURING RECORDchandamalviya
 
Complaints (QUALITY ASSURANCE)
Complaints (QUALITY ASSURANCE)Complaints (QUALITY ASSURANCE)
Complaints (QUALITY ASSURANCE)ShrutiBattinwar
 
Indian GMP Certification & WHO GMP Certification
Indian GMP Certification & WHO GMP CertificationIndian GMP Certification & WHO GMP Certification
Indian GMP Certification & WHO GMP CertificationVishal Shelke
 
Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...
Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...
Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...SimranKukreja4
 
Out of specification shravan
Out of specification shravanOut of specification shravan
Out of specification shravanshravan dubey
 

What's hot (20)

Pharmaceutical Complaints
Pharmaceutical ComplaintsPharmaceutical Complaints
Pharmaceutical Complaints
 
BMR & MFR
BMR & MFRBMR & MFR
BMR & MFR
 
ACTD- ASEAN
ACTD- ASEANACTD- ASEAN
ACTD- ASEAN
 
Pharmaceutical documentation
Pharmaceutical documentationPharmaceutical documentation
Pharmaceutical documentation
 
cGMP.
cGMP.cGMP.
cGMP.
 
Complaints and recall handling
Complaints and recall handlingComplaints and recall handling
Complaints and recall handling
 
BMR (Batch Manufacturing Record)
BMR (Batch Manufacturing Record)BMR (Batch Manufacturing Record)
BMR (Batch Manufacturing Record)
 
ICH Q7 GMP for API
ICH Q7 GMP for APIICH Q7 GMP for API
ICH Q7 GMP for API
 
cGMP
cGMPcGMP
cGMP
 
Market complaints & product recall
Market complaints & product recallMarket complaints & product recall
Market complaints & product recall
 
Vendor qualification
Vendor qualificationVendor qualification
Vendor qualification
 
BATCH MANUFACTURING RECORD
BATCH MANUFACTURING RECORDBATCH MANUFACTURING RECORD
BATCH MANUFACTURING RECORD
 
Good warehouse practice
Good warehouse practiceGood warehouse practice
Good warehouse practice
 
Complaints (QUALITY ASSURANCE)
Complaints (QUALITY ASSURANCE)Complaints (QUALITY ASSURANCE)
Complaints (QUALITY ASSURANCE)
 
Master formula record
Master formula recordMaster formula record
Master formula record
 
Indian GMP Certification & WHO GMP Certification
Indian GMP Certification & WHO GMP CertificationIndian GMP Certification & WHO GMP Certification
Indian GMP Certification & WHO GMP Certification
 
Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...
Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...
Standard operating procedure in pharmaceutical industries,SOP,MFR,Master Form...
 
Good Distribution Practices
Good Distribution PracticesGood Distribution Practices
Good Distribution Practices
 
FDA 483
FDA 483FDA 483
FDA 483
 
Out of specification shravan
Out of specification shravanOut of specification shravan
Out of specification shravan
 

Viewers also liked

SOP For Product Recall
SOP For Product RecallSOP For Product Recall
SOP For Product Recallmuna_ali
 
21 cfr part 806 Process Flow for Device Recalls
21 cfr part 806 Process Flow for Device Recalls21 cfr part 806 Process Flow for Device Recalls
21 cfr part 806 Process Flow for Device RecallsEduQuest, Inc.
 
Complaint and recall handling
Complaint and recall handlingComplaint and recall handling
Complaint and recall handlingDolly Gabriola
 
Product recalls 24.04.13
Product recalls 24.04.13Product recalls 24.04.13
Product recalls 24.04.13Ravikeerthi Rao
 
Complaint handling in pharmaceutical companies,product recall,retention recor...
Complaint handling in pharmaceutical companies,product recall,retention recor...Complaint handling in pharmaceutical companies,product recall,retention recor...
Complaint handling in pharmaceutical companies,product recall,retention recor...swrk
 
Market complaints and product recall
Market complaints and product recallMarket complaints and product recall
Market complaints and product recallpaideeksha
 
Presentation: Revision of the Uniform Recall Procedure for Therapeutic Goods ...
Presentation: Revision of the Uniform Recall Procedure for Therapeutic Goods ...Presentation: Revision of the Uniform Recall Procedure for Therapeutic Goods ...
Presentation: Revision of the Uniform Recall Procedure for Therapeutic Goods ...TGA Australia
 
Media fill process and validation
Media fill process and validationMedia fill process and validation
Media fill process and validationpaideeksha
 
Good Manufacturing Practices
Good Manufacturing PracticesGood Manufacturing Practices
Good Manufacturing PracticesJorge Torres
 
PLRB/LIRB 2012 Claims Conference - Food and Consumer Product Recalls
PLRB/LIRB 2012 Claims Conference - Food and Consumer Product RecallsPLRB/LIRB 2012 Claims Conference - Food and Consumer Product Recalls
PLRB/LIRB 2012 Claims Conference - Food and Consumer Product Recallsbarylgassman
 
when does the fda recall defective medical devices
when does the fda recall defective medical devices when does the fda recall defective medical devices
when does the fda recall defective medical devices SharpLaw
 
Winning confidence of customer
Winning confidence of customerWinning confidence of customer
Winning confidence of customerJyonit Gupta
 
Product recall - Getting it right Leeds 10
Product recall - Getting it right  Leeds 10Product recall - Getting it right  Leeds 10
Product recall - Getting it right Leeds 10Eversheds Sutherland
 

Viewers also liked (20)

SOP For Product Recall
SOP For Product RecallSOP For Product Recall
SOP For Product Recall
 
21 cfr part 806 Process Flow for Device Recalls
21 cfr part 806 Process Flow for Device Recalls21 cfr part 806 Process Flow for Device Recalls
21 cfr part 806 Process Flow for Device Recalls
 
Complaint and recall handling
Complaint and recall handlingComplaint and recall handling
Complaint and recall handling
 
Product recalls 24.04.13
Product recalls 24.04.13Product recalls 24.04.13
Product recalls 24.04.13
 
Complaint handling in pharmaceutical companies,product recall,retention recor...
Complaint handling in pharmaceutical companies,product recall,retention recor...Complaint handling in pharmaceutical companies,product recall,retention recor...
Complaint handling in pharmaceutical companies,product recall,retention recor...
 
Market complaints and product recall
Market complaints and product recallMarket complaints and product recall
Market complaints and product recall
 
Presentation: Revision of the Uniform Recall Procedure for Therapeutic Goods ...
Presentation: Revision of the Uniform Recall Procedure for Therapeutic Goods ...Presentation: Revision of the Uniform Recall Procedure for Therapeutic Goods ...
Presentation: Revision of the Uniform Recall Procedure for Therapeutic Goods ...
 
Media fill process and validation
Media fill process and validationMedia fill process and validation
Media fill process and validation
 
Good Manufacturing Practices
Good Manufacturing PracticesGood Manufacturing Practices
Good Manufacturing Practices
 
PLRB/LIRB 2012 Claims Conference - Food and Consumer Product Recalls
PLRB/LIRB 2012 Claims Conference - Food and Consumer Product RecallsPLRB/LIRB 2012 Claims Conference - Food and Consumer Product Recalls
PLRB/LIRB 2012 Claims Conference - Food and Consumer Product Recalls
 
when does the fda recall defective medical devices
when does the fda recall defective medical devices when does the fda recall defective medical devices
when does the fda recall defective medical devices
 
Boosting Brand
Boosting BrandBoosting Brand
Boosting Brand
 
EEO Complaint Flow Chart
EEO Complaint Flow ChartEEO Complaint Flow Chart
EEO Complaint Flow Chart
 
Winning confidence of customer
Winning confidence of customerWinning confidence of customer
Winning confidence of customer
 
21 CFR PART 11
21 CFR PART 1121 CFR PART 11
21 CFR PART 11
 
Recall Planbooklet
Recall Planbooklet Recall Planbooklet
Recall Planbooklet
 
ML case
ML caseML case
ML case
 
Understanding Food & Drug Recalls
Understanding Food & Drug RecallsUnderstanding Food & Drug Recalls
Understanding Food & Drug Recalls
 
Compliance 02.05.2014
Compliance 02.05.2014Compliance 02.05.2014
Compliance 02.05.2014
 
Product recall - Getting it right Leeds 10
Product recall - Getting it right  Leeds 10Product recall - Getting it right  Leeds 10
Product recall - Getting it right Leeds 10
 

Similar to Recall procedures

drugrecallfinal-200423172250.pptx
drugrecallfinal-200423172250.pptxdrugrecallfinal-200423172250.pptx
drugrecallfinal-200423172250.pptxMonishabasavaraj
 
Presentation Recall of Therapeutic Goods – Overview
Presentation Recall of Therapeutic Goods – Overview Presentation Recall of Therapeutic Goods – Overview
Presentation Recall of Therapeutic Goods – Overview TGA Australia
 
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...TGA Australia
 
Sponsor Information and Training day Session A4 - Medical Devices: Recall and...
Sponsor Information and Training day Session A4 - Medical Devices: Recall and...Sponsor Information and Training day Session A4 - Medical Devices: Recall and...
Sponsor Information and Training day Session A4 - Medical Devices: Recall and...TGA Australia
 
Covid 19 response for pharma companies
Covid 19 response for pharma companiesCovid 19 response for pharma companies
Covid 19 response for pharma companiesaakash malhotra
 
2013 Compliance with Mandatory Reporting Requirements, Regulatory Violations,...
2013 Compliance with Mandatory Reporting Requirements, Regulatory Violations,...2013 Compliance with Mandatory Reporting Requirements, Regulatory Violations,...
2013 Compliance with Mandatory Reporting Requirements, Regulatory Violations,...U.S. Consumer Product Safety Commission
 
Guidelines on food recall
Guidelines on food recallGuidelines on food recall
Guidelines on food recallPRATIBHA SINGH
 
Guidelines on food recall
Guidelines on food recallGuidelines on food recall
Guidelines on food recallpratibha1984
 
Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...
Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...
Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...Michael Swit
 
Deploying A Crisis Management and Business Continuity Approach to Product Tam...
Deploying A Crisis Management and Business Continuity Approach to Product Tam...Deploying A Crisis Management and Business Continuity Approach to Product Tam...
Deploying A Crisis Management and Business Continuity Approach to Product Tam...BCM Institute
 
FDA Warning Letters: Key Legal and Tactical Issues in Dealing with FDA's "Sh...
FDA Warning Letters:  Key Legal and Tactical Issues in Dealing with FDA's "Sh...FDA Warning Letters:  Key Legal and Tactical Issues in Dealing with FDA's "Sh...
FDA Warning Letters: Key Legal and Tactical Issues in Dealing with FDA's "Sh...Michael Swit
 
Sec. 15 Reporting Requirements, Corrective Action Plans, and Investigations
Sec. 15 Reporting Requirements, Corrective Action Plans, and InvestigationsSec. 15 Reporting Requirements, Corrective Action Plans, and Investigations
Sec. 15 Reporting Requirements, Corrective Action Plans, and InvestigationsU.S. Consumer Product Safety Commission
 
Sponsor Information and Training day Session C4 - IVDs: Post-market responsib...
Sponsor Information and Training day Session C4 - IVDs: Post-market responsib...Sponsor Information and Training day Session C4 - IVDs: Post-market responsib...
Sponsor Information and Training day Session C4 - IVDs: Post-market responsib...TGA Australia
 
Complaints and recalls himanshu
Complaints and recalls himanshuComplaints and recalls himanshu
Complaints and recalls himanshuhimanshu kamboj
 

Similar to Recall procedures (20)

drugrecallfinal-200423172250.pptx
drugrecallfinal-200423172250.pptxdrugrecallfinal-200423172250.pptx
drugrecallfinal-200423172250.pptx
 
Recall termination
Recall terminationRecall termination
Recall termination
 
RECALL.pptx
RECALL.pptxRECALL.pptx
RECALL.pptx
 
Presentation Recall of Therapeutic Goods – Overview
Presentation Recall of Therapeutic Goods – Overview Presentation Recall of Therapeutic Goods – Overview
Presentation Recall of Therapeutic Goods – Overview
 
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...
Devices Sponsor Information Day: 5 - Post-market - Recalls and non-recall act...
 
Sponsor Information and Training day Session A4 - Medical Devices: Recall and...
Sponsor Information and Training day Session A4 - Medical Devices: Recall and...Sponsor Information and Training day Session A4 - Medical Devices: Recall and...
Sponsor Information and Training day Session A4 - Medical Devices: Recall and...
 
Covid 19 response for pharma companies
Covid 19 response for pharma companiesCovid 19 response for pharma companies
Covid 19 response for pharma companies
 
2013 Compliance with Mandatory Reporting Requirements, Regulatory Violations,...
2013 Compliance with Mandatory Reporting Requirements, Regulatory Violations,...2013 Compliance with Mandatory Reporting Requirements, Regulatory Violations,...
2013 Compliance with Mandatory Reporting Requirements, Regulatory Violations,...
 
Compliance Program Seminar - Panel 1 - Develop a Compliance Program
Compliance Program Seminar - Panel 1 - Develop a Compliance ProgramCompliance Program Seminar - Panel 1 - Develop a Compliance Program
Compliance Program Seminar - Panel 1 - Develop a Compliance Program
 
Guidelines on food recall
Guidelines on food recallGuidelines on food recall
Guidelines on food recall
 
Guidelines on food recall
Guidelines on food recallGuidelines on food recall
Guidelines on food recall
 
Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...
Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...
Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...
 
Deploying A Crisis Management and Business Continuity Approach to Product Tam...
Deploying A Crisis Management and Business Continuity Approach to Product Tam...Deploying A Crisis Management and Business Continuity Approach to Product Tam...
Deploying A Crisis Management and Business Continuity Approach to Product Tam...
 
FDA Warning Letters: Key Legal and Tactical Issues in Dealing with FDA's "Sh...
FDA Warning Letters:  Key Legal and Tactical Issues in Dealing with FDA's "Sh...FDA Warning Letters:  Key Legal and Tactical Issues in Dealing with FDA's "Sh...
FDA Warning Letters: Key Legal and Tactical Issues in Dealing with FDA's "Sh...
 
Sec. 15 Reporting Requirements, Corrective Action Plans, and Investigations
Sec. 15 Reporting Requirements, Corrective Action Plans, and InvestigationsSec. 15 Reporting Requirements, Corrective Action Plans, and Investigations
Sec. 15 Reporting Requirements, Corrective Action Plans, and Investigations
 
Sponsor Information and Training day Session C4 - IVDs: Post-market responsib...
Sponsor Information and Training day Session C4 - IVDs: Post-market responsib...Sponsor Information and Training day Session C4 - IVDs: Post-market responsib...
Sponsor Information and Training day Session C4 - IVDs: Post-market responsib...
 
Complaints and recalls himanshu
Complaints and recalls himanshuComplaints and recalls himanshu
Complaints and recalls himanshu
 
RECALL PROCEDURES // FOOD SAFETY
RECALL PROCEDURES // FOOD SAFETYRECALL PROCEDURES // FOOD SAFETY
RECALL PROCEDURES // FOOD SAFETY
 
2012 Safety Academy: Fast Track Program
2012 Safety Academy: Fast Track Program2012 Safety Academy: Fast Track Program
2012 Safety Academy: Fast Track Program
 
PMG Newsletter (Volume 03. Issue 07) (12).pdf
PMG Newsletter (Volume 03. Issue 07) (12).pdfPMG Newsletter (Volume 03. Issue 07) (12).pdf
PMG Newsletter (Volume 03. Issue 07) (12).pdf
 

Recently uploaded

How to Solve Singleton Error in the Odoo 17
How to Solve Singleton Error in the  Odoo 17How to Solve Singleton Error in the  Odoo 17
How to Solve Singleton Error in the Odoo 17Celine George
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxMYDA ANGELICA SUAN
 
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxAUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxiammrhaywood
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfTechSoup
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxKatherine Villaluna
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...CaraSkikne1
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17Celine George
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapitolTechU
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxDr. Asif Anas
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and stepobaje godwin sunday
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxheathfieldcps1
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxraviapr7
 
How to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesHow to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesCeline George
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.raviapr7
 
How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17Celine George
 
UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024UKCGE
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17Celine George
 

Recently uploaded (20)

How to Solve Singleton Error in the Odoo 17
How to Solve Singleton Error in the  Odoo 17How to Solve Singleton Error in the  Odoo 17
How to Solve Singleton Error in the Odoo 17
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptx
 
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxAUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptx
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...
 
Prelims of Kant get Marx 2.0: a general politics quiz
Prelims of Kant get Marx 2.0: a general politics quizPrelims of Kant get Marx 2.0: a general politics quiz
Prelims of Kant get Marx 2.0: a general politics quiz
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptx
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptx
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and step
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptx
 
Finals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quizFinals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quiz
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptx
 
How to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesHow to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 Sales
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.
 
How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17
 
UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024UKCGE Parental Leave Discussion March 2024
UKCGE Parental Leave Discussion March 2024
 
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdfPersonal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17
 

Recall procedures

  • 2. TABLE OF CONTENTS: I. Recall Page # 3 II. FDA responsibilities Page # 4 i. Responsibilities of OE/DCMO Page # 5 ii. Responsibilities & procedures - OE/DCP Page # 6 iii. Responsibilities & procedures – OE/DCIQA Page #6 III. Recall Enterprise System (RES) Page # 7 IV. Center Recall Unit (CRU) Page # 8 V. Health Hazard Evaluation (HHE) Page # 9 VI. Recall Initiation Page # 10 VII. Recall Classification Page # 11 i. Class I Recall Page # 12 ii. Class II Recall Page # 13 iii. Class III Recall Page # 14 VIII. Alerting the public Page # 15 IX. Monitoring Recall Effectiveness Page # 16 X. Termination of Recall Page # 17-18 XI. Responsibilities of Recalling Firm Page # 19 i. Preparing of the Recall Page # 20 ii. Determining the Scope of the Recall Page # 21 iii. Determining the Depth of the Recall Page # 22 iv. Communicating with FDA Page # 23 v. Communicating with Consignees Page # 25 vi. Press release Page # 25 XII. Drug Recalls in 2013. Page # 26-28 07/15/13 2
  • 3. RECALL • Recall means a firm’s removal or correction of a marketed product(s) that the Food and Drug Administration considers to be in violation of the laws it administers and against which the agency would initiate legal action, e.g., seizure. OR • Recalls are an alternative appropriate method of removing or correcting marketed consumer products, their labeling, and/or promotional literature that violates the laws administered by FDA. 07/15/13 3
  • 4. FDA RESPONSIBILITIES • FDA is involved in recall procedures. • Monitor the recall by reviewing firm’s status reports and conducting audit checks (District) • Discuss and approve recall strategy –including press releases (District/Center -Office of Public Affairs for press) • Classify the recall (Center) • Terminate the recall (District Class II and III; Center approval for class I) • FDA will take appropriate regulatory action or other measures when the firm fails to recall violative product or when a recall action fails. • These actions will be taken in consultation and coordination with the district compliance branch, the appropriate center recall and compliance staffs, OE/DCMO and when indicated, the officer of Chief Counsel, when: – A firm refuses to recall or sub-recall after being requested to do so by FDA; – A firm fails to complete recall in a timely fashion; – The agency has reason to believe that a recall strategy is not effective. 07/15/13 4
  • 5. • Responsibility of Office of Enforcement / Division of Compliance Management and Operations –OE/ DCMO is the agency’s headquarters contact and focal point for information, advice, and direction for field recall operations and remains involve with each recall throughout its process. –If required, it may direct appropriate follow up actions by the field. –It periodically reviews all agency recall activities to ensure that current policy & procedures are being applied to recalls and recommends changes are appropriate. –It informs OE/DCIQA of recalls that may affect govt. agencies. –It evaluates the overall effectiveness of recall activities. –It communicates trends, common cause of recalls, control weakness, etc., having the needs for this information. 07/15/13 5
  • 6. • Responsibilities & Procedures - Office of Enforcement/ Division of Compliance Policy –OE/DCP reviews and resolves compliance policy issues related to recalls. –The division reviews recall action memorandums when requested by OE/DCMO. –OE/DCP provides written response to OE/DCMO. • Responsibilities & Procedures - Office of Enforcement/Division of Compliance information & Quality Assurance –OE/DCIQA receives recall information from OE/DCMO when the identified consignees include government agencies. –It forwards the information, as appropriate, to the applicable government agencies. 07/15/13 6
  • 7. RECALL ENTERPRISE SYSTEM • The Recall Enterprise System (RES)is an electronic data system used by FDA recall personnel to submit, update, classify, & terminate recalls. • The RES increases efficiency in processing recall information by: – Allowing field coordinators to input recall information via on-line, internet system; – Allowing users to build a record of the entire recall by entering information as it becomes available thus reducing preparation time and providing consistency throughout the agency; – Reducing duplication of efforts between the Field officer, OE, the centers, and Office of public affairs; – Increasing communication of recall information between field, headquarters and the appropriate center(s) office; – Using a uniform Health Hazard Evaluation (HHE) form or a form equivalent to HHE form to promote consistency in evaluating potential health hazards; – Providing the public with “real-time” information about the FDA recall process. 07/15/13 7
  • 8. CENTER RECALL UNIT(CRU) • The Center recall unit: 1. Initiates a health hazard evaluation (HHE) 2. Finalizes a recall strategy 3. Classifies the recall and, for Class I recalls, prepares an Action memorandum for Center Director or his/her designee concurrence before forwarding it to OE/DCMO and the ACRA; and, 4. Updates RES with classification, audit strategy, and any recommendations, and posts the information to the internet. 07/15/13 8
  • 9. HEALTH HAZARD EVALUATION •Diseases or injuries which have already occurred •Existing conditions that can contribute to a clinical condition •Population •Seriousness of hazard •Likelihood of occurrence of hazard •Immediate and long term consequences 07/15/13 9
  • 10. RECALL INITIATION • Recall may initiated in three ways: 1. Firm initiated Recalls: A manufacturer or distributor may voluntarily initiate a recall at any time. 2. FDA requested Recalls: Under certain urgent situations, FDA may request that a manufacturer or distributor recall a product. 3. FDA Ordered Recalls: Under certain authorities, FDA may mandate a recall. It includes: – Mandatory Device recalls – Mandatory of biological products – Mandatory recall of human tissue intended for transplantation – Infant formula – Interstate milk shipments – Tobacco products 07/15/13 10
  • 11. RECALL CLASSIFICATION • Numerical designation (i.e., I, II, or III) is assigned by FDA to a particular product recall to indicate the relative degree of health hazard presented by the product being recalled. 07/15/13 11
  • 12. • CLASS I RECALLS Class I is a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. Examples of Class I Recalls •Pathogens in ready-to-eat food: Salmonella, Listeria monocytogenes, E. coli, Clostridium •High levels of sulfites •High levels of heavy metals •Choking hazards for susceptible populations 07/15/13 12
  • 13. • CLASS II RECALLS Class II is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Examples of Class II Recalls •Foreign objects that pose a physical hazard •Pathogens: Shigella, hepatitis A, Cyclospora, Cryptosporidium 07/15/13 13
  • 14. • CLASS III RECALLS Class III is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences. • Example of Class III Recalls An example might be bottles of aspirin that contains 90 tablets instead of the 100 stated on the label. 07/15/13 14
  • 15. ALERTING THE PUBLIC • FDA seeks publicity about a recall only when it believes the public needs to be alerted to a serious hazard. • When a recalled product has been widely distributed, the news media is a very effective way to reach large numbers of people. • FDA can hold press conferences, issue press releases, and post updates to its Web site regularly, to alert people. • Not all recalls are announced in the media. But all recalls go into FDA's weekly Enforcement Report. This document lists each recall according to classification, with the specific action taken by the recalling firm. • "It's about being as transparent as possible," says Catherine McDermott, public affairs manager in the Division of Federal-State Relations in FDA's Office of Regulatory Affairs. "If we feel there is that much of a health risk, we will offer media updates every day to give new information, and all that we know gets posted to FDA's Web site." 07/15/13 15
  • 16. MONITORING RECALL EFFECTIVENESS • FDA evaluates whether all reasonable efforts have been made to remove or correct a product. • A recall is considered complete after all of the company's corrective actions are reviewed by FDA and deemed appropriate. • After a recall is completed, FDA makes sure that the product is destroyed or suitably reconditioned, and investigates why the product was defective in the first place • A recalling firm may be unable to check the effectiveness of its recall when a recall extends to the consumer-user level, the confidential business record of a firm’s customers are not accessible, wholesalers, distributors or retailors do not cooperate, or because an urgency of the situation requires an all-out effort. • In such cases, when a recalling firm unable to check its effectiveness, FDA will directly assist in this activity and, where necessary, seek assistance from cooperating state and local agencies. 07/15/13 16
  • 17. TERMINATION OF RECALL • FDA will terminate a recall when the monitoring district office determines that the recalling firm has completed all recall activity, including monitoring and final product disposition. • The district will notify the recalling firm by a letter that FDA considers the recall terminated. • Termination of Class I recall and a Safety Alert requires center concurrence. When the monitoring district concludes that such a recall and a Safety Alert has been completed, the district recall coordinator will enter the information required for termination in RES on the “Summary & Termination “ page then verify the information then send an email to the CRU recommending termination. 07/15/13 17
  • 18. • Upon receipt of the termination recommendation email, the CRU will access RES, review the termination information and change the “recall status” field to “terminated” and generates an email to the district and OE/DCMO advising that the recall is terminated • Center approval is not required for Class II and III recall terminations. • As a rule FDA should terminate the recall within three months after the firm completes the recall. 07/15/13 18
  • 20. Preparing for a recall • Review available recall guidance • Develop a recall plan • Maintain manufacturing and distribution records in a manner to facilitate a timely and effective recall • Identify finished products with a lot number/code 07/15/13 20
  • 21. Determining the scope of the recall. •When did the problem start/end? •Can additional lots/products be affected other than the lot/product analyzed and found adulterated? •How many sizes/labels for the product? •Is the product coded with a lot number? •Shelf life of product 07/15/13 21
  • 22. Determining the depth of the recall •Class I recalls generally to consumer/user depth via press release •Class II generally to retail depth; some to consumer/user via press release •Class III generally to retail depth when problem when problem obvious to consumer 07/15/13 22
  • 23. Communicating with the FDA • Notify FDA District Recall Coordinator and provide information in a timely manner • Info needed by FDA includes: – Product (identity, size and type of containers, brand names, lot numbers, whether refrigerated/frozen/shelf stable) – Codes – Amount manufactured and amount distributed – Number of and types of consignees – Area of distribution – Reason for recall • Discuss recall strategy with FDA (including disposition of recalled product) • Let FDA review text of phone notifications, written recall notifications, press releases (follow models provided in FDA guidance) • Provide FDA with consignee list • Provide actual labels or clear photos of labels07/15/13 23
  • 24. Communicating with Consignees •Be brief and to the point •Identify clearly the product, size, lot number(s), code(s) or serial number(s) and any other pertinent descriptive information to enable accurate and immediate identification of the product •Explain concisely the reason for the recall and the hazard involved, if any •Provide specific instructions on what should be done with respect to the recalled products •Provide a ready means for the recipient of the communication to report to the recalling firm whether it has any of the product •Provide sub-recall instructions (if necessary) •Re-contact non-responders and conduct effectiveness checks 07/15/13 24
  • 25. Press release •Follow FDA models as closely as possible –“fill in the blanks” •Do not change hazard statement –don’t take out “life threatening” •Issue press release to Associated Press •Provide FDA with confirmation that press release was sent to AP •FDA will issue if firm will not or if firm’s is inadequate 07/15/13 25
  • 26. DRUG RECALLS in 2013 07/15/13 26
  • 27. drugsrecall in 2013 Date Brand Name Product Description Reason/ Problem Company 07/03/2013 Estarylla Estarylla (norgestimate and ethinyl estradiol) tablets Report of a placebo tablet present in a row of active tablets Sandoz 06/30/2013 Nexus, APP Benztropine Mesylate Injection Glass particles Fresenius Kabi USA 06/19/2013 Rugby Enteric Coated Aspirin Tablets,81 mg May Contain Acetaminophen 500 mg tablets Advance Pharmaceutical Inc. 06/13/2013 Sagent Pharmaceuticals, Inc. Vecuronium Bromide for Injection Due to elevated impurity levels Sagent Pharmaceuticals, Inc. 06/11/2013 Bethel Weight Loss Pills Contains Undeclared Drug Ingredient Bethel Nutritional Consulting, Inc. 06/10/2013 ZyGenerics Warfarin 2 mg Tablets Oversized tablet Zydus Pharmaceuticals USA Inc. 06/07/2013 Sagent Pharmaceuticals, Inc. Vecuronium Bromide for Injection Due to elevated impurity levels Sagent Pharmaceuticals, Inc. 07/15/13 27http://www.fda.gov/Safety/Recalls/default.htmhttp://www.fda.gov/Safety/Recalls/default.htm
  • 28. 07/15/13 28 Date Brand name Product Description Problem/Reason Company 05/29/2013 Lowlite, Olympia Pharmacy All Sterile Products Potential for non- sterility Lowlite Investments, Olympia Pharmacy 05/28/2013 Main Street Family Pharmacy All Sterile Products Potential for non- sterility Main Street Family Pharmacy, LLC 05/25/2013 Fresenius Kabi USA Magnesium Sulfate Injection USP Glass Particles Fresenius Kabi USA 05/21/2013 JaDera, Xiyouji Qingzhi Weight loss supplement Unapproved New Drug Dolphin Intertrade Corp 05/20/2013 Sandoz Methotrexate Sodium, USP, 25 mg/mL, 40 mL vial injectable vials Particulate material in vials Sandoz US 05/15/2013 Pentec Health In-date nutritional prescriptions for renal patients Lack of sterility assurance Pentec Health 05/10/2013 Hospira Piperacillin and Tazobactam for Injection Precipitation/Cryst allization in IV bag Apotex Corp. http://www.fda.gov/Safety/Recalls/default.htm